Literature DB >> 17986566

Improving outcome in geriatric peritoneal dialysis patients.

Makoto Hiramatsu1.   

Abstract

OBJECTIVE: Few data are available about elderly patients on peritoneal dialysis (PD). In the present study, we reviewed our experience with patients aged 70 years or more at the start of peritoneal dialysis (PD).
DESIGN: This retrospective study was conducted at a single center in Japan. PATIENTS AND METHODS: Of 222 patients managed using PD at our hospital between 1991 and 2001 (including 219 cases of PD first), 150 patients were aged under 70 years and 72 patients were 70 years of age or older. For the two groups of patients, we determined clinical data, erythropoietin and PD prescriptions, reasons for selecting PD (elderly patients only), urine and ultrafiltration volumes, comprehensive functional assessment, quality of life (QOL), comorbidity, technique survival rate, and causes of death.
RESULTS: Serum creatinine, serum beta(2)-microglobulin, total dose of erythropoietin (EPO) needed to maintain hematocrit at 30%, number of continuous ambulatory peritoneal dialysis (CAPD) exchanges, and total volume of dialysis solution prescribed were significantly lower in the elderly patients as compared with patients aged under 70 years. The main reasons for starting PD in elderly patients at our hospital were advanced age (57%), patient's choice (25%), and cardiovascular complications (9%). Residual renal function was well maintained in CAPD patients aged 70 years or more as compared with patients aged under 70 years. Ultrafiltration volume was lower in the elderly CAPD patients. Scores on the Revised Hasegawa Dementia Scale, the Physical Self-Maintenance Scale, and the Instrumental Activities of Daily Living scale were significantly higher in CAPD patients than in hemodialysis patients. Subjective assessment using a linear analog scale showed a high QOL score in the elderly patients for overall feelings of well-being, mood, and anxiety. At the time of dialysis introduction, the major existing disorders in patients over 80 years of age were mostly cardiovascular disorders such as heart failure, myocardial infarction, serious arrhythmia, and cerebrovascular disease. The median technique survival in patients aged 70 years or more was 31.5 months. The main causes of death in elderly PD patients were heart failure (35.7%), peritonitis (14.3%), and cerebrovascular disease (11.9%).
CONCLUSION: Peritoneal dialysis should be considered the treatment method of choice when introducing dialysis in elderly patients.

Entities:  

Mesh:

Year:  2003        PMID: 17986566

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  5 in total

1.  Quality of life of elderly patients on peritoneal dialysis versus hemodialysis: a single-center study.

Authors:  Yosuke Saka; Tomohiko Naruse; Naoto Tawada; Mitsuhiro Tokomoto; Yuhei Noda; Yohei Taniguchi; Yasuko Nagahara; Ryoko Yamashita; Munetoshi Karasawa; Yuzo Watanabe; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2016-12-20       Impact factor: 2.801

Review 2.  The Needs of Older Patients for Peritoneal Dialysis: Training and Support at Home.

Authors:  Helen Hurst; Ana E Figueiredo
Journal:  Perit Dial Int       Date:  2015-11       Impact factor: 1.756

3.  Perioperative Management and Surgical Outcomes of Colorectal Cancer Patients Undergoing Peritoneal Dialysis for End-Stage Kidney Disease.

Authors:  Nobuji Kouno; Ryo Takahashi; Takumi Furuya; Takahisa Fujikawa
Journal:  Cureus       Date:  2022-07-09

4.  Withdrawal from Dialysis and Palliative Care for Severely Ill Dialysis Patients in terms of Patient-Centered Medicine.

Authors:  Hideaki Ishikawa; Nao Ogihara; Saori Tsukushi; Junichi Sakamoto
Journal:  Case Rep Nephrol       Date:  2013-12-04

5.  Relationship between Icodextrin use and decreased level of small low-density lipoprotein cholesterol fractioned by high-performance gel permeation chromatography.

Authors:  Eiichiro Kanda; Masumi Ai; Asami Iwamoto; Mitsuyo Okazaki; Yoshitaka Maeda; Sei Sasaki; Masayuki Yoshida
Journal:  BMC Nephrol       Date:  2013-10-26       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.